Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.

CEO

ISIN

CA23256X1006

Listings

0 Comments

Share your thoughts

FAQ

What is Cybin stock price today?▼

The current price of R7E1.STU is €0.22 EUR — it has decreased by -14.74% in the past 24 hours. Watch Cybin stock price performance more closely on the chart.

What is Cybin stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Cybin stocks are traded under the ticker R7E1.STU.

Is Cybin stock price growing?▼

R7E1.STU stock has fallen by -1.7% compared to the previous week, the month change is a +53.91% rise, over the last year Cybin has showed a -17.3% decrease.

What is Cybin market cap?▼

Today Cybin has the market capitalization of 13.48M

When is the next Cybin earnings date?▼

Cybin is going to release the next earnings report on August 06, 2026.

In which sector is Cybin located?▼

Cybin operates in the Other sector.

When did Cybin complete a stock split?▼

Cybin has not had any recent stock splits.